BioAtla Q2 net loss $18.7M; cash $18.2M; Oz-V 45% ORR in HPV+ OPSCC

BioAtla, Inc.

2025-Q2 EPS reported -$0.58

Net loss of $18.7M for Q2 2025 vs $21.1M in Q2 2024; R&D expense down to $13.7M.
Cash and cash equivalents $18.2M as of June 30, 2025, down from $49.0M at Dec 31, 2024.
BA3182 (EpCAM x CD3 TCE) Phase 1 dose-escalation ongoing; data readout expected 2H 2025.
Oz-V (CAB-ROR2-ADC) shows 45% ORR (5/11) in 2L+ HPV+ OPSCC; FDA meeting planned in 3Q 2025.
Company advancing partnering discussions; confident in closing at least one transaction in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.